E Fund Management (HK)’s GSK GSK Stock Holding History

E Fund Management (HK)’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.7K	Buy	433 +169	+64%	+$8.94K	0.01%	290
2026 Q1	$14.6K	Buy	+264	New	+$14.3K	0.01%	267

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

E Fund Management (HK)'s GSK Position: Q2 2026 in Review

E Fund Management (HK) increased its GSK (GSK) stake by 64% in Q2 2026, buying an estimated $8.94K and bringing the position to 433 shares worth $22.7K. The position accounts for 0.01% of the portfolio, ranked #290.

E Fund Management (HK) first reported a position in GSK in Q1 2026 and has held it in 2 quarters since. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

E Fund Management (HK) held 433 shares of GSK worth $22.7K as of Q2 2026.
E Fund Management (HK) bought 169 GSK shares in Q2 2026, an estimated $8.94K.
GSK made up 0.01% of E Fund Management (HK)'s portfolio in Q2 2026, its #290 holding.
E Fund Management (HK) first reported a position in GSK in Q1 2026 and has held it in 2 quarters since.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on E Fund Management (HK)'s 13F filing for Q2 2026, filed 22 Jul 2026.